HBV Reactivation - Screening and Prophylaxis

Key Points

• Screen with HBsAg and total anti-HBc before significant immunosuppression; anti-HBs helps define immune status.
• Resolved HBV infection can reactivate, especially during B-cell-depleting therapy or stem-cell transplantation.
• High-risk patients should receive prophylaxis rather than waiting for ALT elevation.
• Use entecavir or tenofovir-class therapy because of high antiviral potency and resistance barrier.
• Start prophylaxis before or at the beginning of immunosuppression and continue after therapy ends.
• Lower-risk anti-HBc-positive patients may be monitored instead of prophylaxed only when reliable HBV DNA follow-up is feasible.
• Reactivation can cause acute liver failure and can interrupt essential cancer or immune therapy.

Algorithm

1. Before immunosuppression, obtain HBsAg, total anti-HBc, anti-HBs, ALT, and HBV DNA when serology indicates current or prior infection.
2. Determine whether chronic HBV already requires treatment.
3. Classify reactivation risk by serology and immunosuppressive regimen.
4. Start entecavir or tenofovir prophylaxis for HBsAg-positive patients and high-risk resolved infection.
5. For selected lower-risk resolved infection, establish scheduled HBV DNA and ALT monitoring before treatment starts.
6. Continue prophylaxis for the guideline-recommended period after immunosuppression, longer for B-cell-depleting regimens.
7. Treat breakthrough reactivation promptly and involve hepatology.

Clinical Synopsis & Reasoning

Hepatitis B reactivation ranges from asymptomatic HBV DNA increase to severe hepatitis, acute liver failure, interruption of cancer therapy, and death. It can occur in patients who are HBsAg positive and also in patients with resolved infection who are HBsAg negative but anti-HBc positive. Risk depends on baseline viral status and the intensity and mechanism of immunosuppression. B-cell-depleting agents such as rituximab and hematopoietic stem-cell transplantation carry particularly high risk even after apparently resolved infection.

Screen before immunosuppressive or cytotoxic therapy using HBsAg and total anti-HBc, with anti-HBs included to clarify immune status. If HBsAg or anti-HBc is positive, obtain baseline HBV DNA and liver tests and determine whether the patient already meets criteria for chronic HBV treatment independent of the planned immunosuppression. Anti-HBs positivity lowers but does not eliminate reactivation risk in anti-HBc-positive patients.

Risk categories differ among guidelines and regimens, so prophylaxis should be linked to the specific agent rather than to a generic label of chemotherapy. Anti-CD20 therapy, stem-cell transplantation, and prolonged high-dose corticosteroids are examples that may justify prophylaxis depending on serologic status. Lower-risk regimens can sometimes be managed with close HBV DNA and ALT monitoring instead of universal antivirals when reliable follow-up is assured.

Treatment Strategy & Disposition

Use a high-barrier nucleos(t)ide analog such as entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide for prophylaxis. Start before or at initiation of the immunosuppressive regimen whenever possible. Continue throughout immunosuppression and for an adequate period afterward because reactivation can occur after immune recovery; longer post-treatment prophylaxis is used after B-cell-depleting therapy and stem-cell transplantation.

Patients who are HBsAg positive generally require prophylaxis or full chronic-HBV treatment during clinically significant immunosuppression. HBsAg-negative, anti-HBc-positive patients receiving anti-CD20 therapy or stem-cell transplantation should receive prophylaxis rather than monitoring alone. For lower-risk regimens, serial ALT, HBsAg, and HBV DNA monitoring at a guideline-consistent interval may be reasonable if follow-up is reliable and antiviral therapy can begin immediately when reactivation is detected.

Coordinate hepatology, oncology, rheumatology, or transplant care because stopping the anticancer or immune therapy unnecessarily can also be harmful. Choose antiviral therapy based on renal function, bone disease, pregnancy potential, prior antiviral resistance, and other chronic-HBV factors. Do not use lamivudine when prolonged prophylaxis is expected and a high-resistance-barrier agent is available.

Epidemiology / Risk Factors

• HBV reactivation risk is highest in HBsAg-positive patients but remains important after resolved infection with certain regimens.
• Rituximab and other anti-CD20 agents are classic high-risk exposures.
• Risk varies by geographic HBV prevalence because more patients in endemic regions have prior infection.
• Failure to screen before chemotherapy remains a preventable cause of severe hepatitis.

Investigations

Who Gets Prophylaxis

Pharmacology

Prognosis / Complications

• Prophylaxis markedly reduces clinically significant HBV reactivation in high-risk patients.
• Untreated reactivation can cause fulminant hepatitis, death, or interruption of curative cancer therapy.
• Most patients respond to potent nucleos(t)ide therapy when reactivation is recognized early.
• Long-term antiviral treatment may be required when the patient independently meets chronic-HBV treatment criteria.

Patient Education / Counseling

• Explain that prior hepatitis B can become active again when the immune system is suppressed even if infection seemed resolved.
• Emphasize taking prophylactic antiviral medicine consistently through the planned post-treatment period.
• Do not stop antiviral therapy when chemotherapy ends without confirming the follow-up plan.
• Report jaundice, dark urine, severe fatigue, abdominal swelling, or confusion urgently.

Notes

HBV reactivation is a prevention problem. The safest moment to manage it is before the first dose of immunosuppression, when serology can be reviewed calmly and prophylaxis can begin without interrupting the primary treatment.

The specific regimen matters. A patient with remote resolved HBV who might reasonably be monitored during a lower-risk therapy may need mandatory prophylaxis when treated with an anti-CD20 agent.

References

1. AASLD Hepatitis B Clinical Practice Guideline — Link
2. AASLD Clinical Pearls: Hepatitis B Reactivation — Link